Verve therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Boston, june 02, 2025 (globe newswire) -- verve therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on may 30, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 inducement stock incentive plan, as an inducement material to each new employee entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking